Atara Biotherapeutics Inc
Latest Atara Biotherapeutics Inc News and Updates
Baupost discloses stake in Paratek Pharmaceuticals
Seth Klarman’s The Baupost Group added a 12.04% stake in Paratek Pharmaceuticals, Inc. (PRTK), according to a 13G filing in December.
Inside Atara Biotherapeutics’ Promising Product Pipeline
Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.
Forward Pharma: One of Baupost’s new positions
Seth Klarman’s The Baupost Group added a 11.72% stake in Forward Pharma (FWP). A November 13G filing shows the fund owns 5,367,300 Forward Pharma shares.
Baupost nearly doubles position in Cheniere Energy
In its 13G filing in January, The Baupost Group upped its stake in Cheniere Energy (LNG), giving it 10.01% stake in LNG and nearly doubling its 3Q14 filing.
